Effectiveness and safety of tocilizumab, an anti–interleukin-6 receptor antibody, in 342 Japanese patients with multicentric Castleman disease: a 3-year, prospective, observational study
Norihiro Nishimoto, Miho Murakami, Takeshi Johkoh, Seiji Hayashi, Shiro Ohshima, Masao Mizuki, Takahiro Kakehi, Yuichi Kawata 等 11 位
The University of Osaka Kansai Rosai Hospital NHO Kinki Chuo Chest Medical Center Osaka Minami Medical Center
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
OBJECTIVES: Multicentric Castleman disease (MCD) is a rare lymphoproliferative disorder characterized by multifocal lymphadenopathy and systemic inflammatory symptoms. This single-arm, prospective, observational, postmarketing surveillance (UMIN000023071) assessed the real-world effectiveness and safety of tocilizumab in Japanese patients with MCD. METHODS: Patients with MCD received tocilizumab intravenous infusion 8 mg/kg every 2 weeks for up to 3 years. Effectiveness outcomes included enlarged lymph node regression; improvement in laboratory findings, associated symptoms, and organ involvement; and change in corticosteroid doses. Safety was assessed through adverse events (AEs). RESULTS: A total of 342 patients were included. Tocilizumab was continued for >152 weeks in 70.1% of patients. After treatment, 58.9% of patients showed lymph node regression. Laboratory test values were improved, and most evaluable patients reported improvements in associated symptoms, including night sweats, anorexia, fever, and fatigue. Organ involvement, including pulmonary disease, rash, and hepatosplenomegaly, was 'improved' or 'stable' in more than half of evaluable patients. Tocilizumab treatment resulted in corticosteroid dose reduction. The most commonly reported AEs were infections and infestations; respiratory, thoracic, and mediastinal disorders; and gastrointestinal disorders. CONCLUSIONS: The effectiveness and safety of tocilizumab in Japanese patients with MCD was confirmed for up to 3 years, without new safety concerns.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Viral-associated cancers and disorders
Autoimmune and Inflammatory Disorders Research · Lymphadenopathy Diagnosis and Analysis